Willner & Heller LLC Takes Position in AstraZeneca PLC (NASDAQ:AZN)

Willner & Heller LLC acquired a new position in shares of AstraZeneca PLC (NASDAQ:AZNFree Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 4,662 shares of the company’s stock, valued at approximately $314,000.

A number of other institutional investors also recently added to or reduced their stakes in AZN. Fisher Asset Management LLC lifted its position in AstraZeneca by 2.2% during the 4th quarter. Fisher Asset Management LLC now owns 9,376,193 shares of the company’s stock worth $631,487,000 after acquiring an additional 205,185 shares during the period. American International Group Inc. boosted its position in AstraZeneca by 2.0% in the fourth quarter. American International Group Inc. now owns 40,464 shares of the company’s stock valued at $2,725,000 after buying an additional 775 shares during the last quarter. EP Wealth Advisors LLC boosted its position in AstraZeneca by 11.7% in the fourth quarter. EP Wealth Advisors LLC now owns 17,481 shares of the company’s stock valued at $1,177,000 after buying an additional 1,837 shares during the last quarter. Abel Hall LLC acquired a new position in AstraZeneca in the 4th quarter worth approximately $248,000. Finally, Beaird Harris Wealth Management LLC raised its position in AstraZeneca by 8.9% during the 4th quarter. Beaird Harris Wealth Management LLC now owns 1,851 shares of the company’s stock worth $125,000 after buying an additional 151 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Up 0.1 %

NASDAQ AZN traded up $0.06 on Friday, hitting $79.59. 2,055,322 shares of the stock were exchanged, compared to its average volume of 3,761,780. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $80.86. The company has a 50-day moving average price of $75.46 and a 200-day moving average price of $69.40. The company has a quick ratio of 0.70, a current ratio of 0.89 and a debt-to-equity ratio of 0.73. The company has a market cap of $246.77 billion, a PE ratio of 39.01, a PEG ratio of 1.43 and a beta of 0.48.

AstraZeneca (NASDAQ:AZNGet Free Report) last announced its quarterly earnings results on Thursday, April 25th. The company reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.95 by $0.08. AstraZeneca had a return on equity of 30.42% and a net margin of 13.30%. The company had revenue of $12.68 billion during the quarter, compared to the consensus estimate of $11.92 billion. Sell-side analysts anticipate that AstraZeneca PLC will post 4.04 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. BMO Capital Markets boosted their price objective on AstraZeneca from $80.00 to $82.00 and gave the company an “outperform” rating in a report on Friday, April 26th. Argus boosted their price target on AstraZeneca from $80.00 to $85.00 and gave the company a “buy” rating in a report on Thursday, May 30th. The Goldman Sachs Group assumed coverage on shares of AstraZeneca in a research note on Thursday, May 30th. They set a “buy” rating and a $97.00 price objective on the stock. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, April 16th. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, AstraZeneca presently has an average rating of “Moderate Buy” and a consensus price target of $88.00.

Get Our Latest Report on AstraZeneca

AstraZeneca Profile

(Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Featured Articles

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZNFree Report).

Institutional Ownership by Quarter for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.